23 Jul, 2026
According to Straits Research, the global cell separation technologies market size was valued at $10.38 billion in 2025 and is estimated to reach $25 billion by 2034, registering a CAGR of 10.55% during the forecast period (2026–203
Through intracellular or extracellular characteristics, cells are separated from a heterogeneous cell mixture using cell separation technology. Since cell separation is crucial to cellular therapy and illness diagnostics, it has acquired significance in the domains of medicine and biology. The prevalence of chronic diseases including cancer, diabetes, cardiovascular diseases (CVDs), and many others is also increasing, leading to cell separation technology's use for diagnostic and therapeutic purposes.
The bulk of these diseases can be treated using cell-based therapies. Therefore, the recent growth in cell separation is associated with a rise in the mortality rate from chronic diseases. The increase in patients with chronic diseases and technological improvements in cell technologies are the two main factors driving the growth of the global market for cell separation technologies. Additionally, there is a growing emphasis on tailored medications for disease early diagnosis, treatment selection, and therapy prognosis assessment.
Rising Instances of Chronic Diseases Propel the Global Cell Separation Technologies Market
The high prevalence of chronic diseases and infectious diseases is increasing globally. Chronic diseases such as cancer, heart disease, stroke, type II diabetes, and obesity are growing due to sedentary lifestyles, an aging population, increased alcohol consumption, and cigarette smoking. According to the World Health Organization (WHO), in 2020, the mortality rate from chronic diseases reached 73%. In developing regions, 70% of deaths are caused by chronic diseases. In addition, chronic diseases are expected to affect China, India, and Africa significantly. Furthermore, the global burden of cancer is expected to continue to grow by 45% between 2008 and 2030. Consequently, rising investment in cell-based research for cancer by biopharmaceutical companies and research laboratories is a prime factor attributing to the growth of this market.
Emerging Markets Create Lucrative Opportunities for Cell Separation Technologies
Cell separation technology has a lot of room to grow in emerging markets like Asia-Pacific and LAMEA. This is attributed to the rising investments in cell-based research and the expanding market share of players in emerging areas. For instance, Indian-based pharmaceutical businesses invest a lot in R&D to bring novel medications to market. Due to such expenditures, the country's demand for products utilizing cell separation technology is anticipated to rise in the upcoming years. The government is expected to embrace more cutting-edge tools and technologies to boost productivity due to the rising R&D activity in the pharmaceutical and biotechnology industries.
North America is the highest revenue contributor and is estimated to grow at a CAGR of 14.1% during the forecast period. Due to its highly developed healthcare sector, significant R&D expenditures, rising product approval rates, and numerous cell separation technology manufacturers in the region, North America is anticipated to hold a dominant share of the global cell separation technology market during the forecast period. For instance, in July 2020, a US-based company, Corning Incorporated, launched the Corning X-SERIES cell processing platform.
Asia-Pacific is the fastest-growing region. Asian governments are investing in creating healthcare infrastructure for ongoing stem cell and cancer research to create cutting-edge treatments for patients and medical personnel. Government programs to support the biotechnology sector are creating chances for rivals. New players are benefitting by expanding their portfolios with advanced breakthrough technologies. Concentrating investments in technologies ideal for stem cell and cancer research could further boost the market. Additionally, the rise in healthcare awareness about cell separation and growth in per capita healthcare expenditure in developing countries also provide opportunities for growth in the cell separation technology market.
Europe is the second-largest region and is projected to reach USD 14,650 million by 2030, growing at a CAGR of 15%. Germany, France, the UK, and other European counties are expected to grow at a significant pace during the forecast period, owing to increased healthcare expenditure, product advancement, and modernization of healthcare facilities. For instance, in April 2020, Europe-based company Alfa Laval launched the first premium separator system for single-use pharmaceutical processing. It was used in processes for harvesting fragile cell cultures, which can later be used for injectable drugs to treat life-threatening illnesses such as cancer, rheumatoid arthritis, and organ transplant rejection.
sales@straitsresearch.com